Curaleaf Q2 2026 earnings show revenue at $340M, a 10% YoY increase. Net income rises to $12.5M, marking a significant turnaround from last year.
Curaleaf Holdings Inc. reported Q2 2026 revenue of $340 million (USD), an increase of 10% year-over-year and surpassing consensus expectations. The strong performance reflects the company's successful execution of its operational strategy, particularly in domestic and international markets, while also benefiting from regulatory tailwinds.
Key Takeaways
- Revenue reached $340 million, up 10% YoY and 5% sequentially, driven by both domestic (up 7%) and international (up 26%) growth.
- Gross margin improved to 50%, aided by enhanced cultivation efficiency and disciplined labor expense controls, despite pressures from international pricing.
- Net income from continuing operations was $12.5 million or $0.05 per share, compared to a net loss of $48 million in the prior year, bolstered by significant tax benefits.
- Adjusted EBITDA increased by 3% YoY to $70 million, maintaining a 21% margin.
- Retail revenue was $241 million, up 5% YoY, while wholesale revenue surged by 28% to $96 million, comprising 28% of total revenue.
Revenue Growth Driven by Operational Improvements
Curaleaf's revenue for Q2 2026 reached $340 million, marking a 10% increase year-over-year and a 5% sequential rise. The growth was primarily fueled by domestic sales, which rose 7%, and international sales, which surged 26%. The domestic segment benefited from improved execution across various states, including double-digit growth in Ohio, Utah, New York, and Florida, showcasing a broad-based recovery rather than dependence on a single market.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $340M | +10% | +5% |
| Gross Margin | 50% | +170 bps | 0 |
| Adjusted EBITDA | $70M | +3% | 0 |
| Net Income | $12.5M | N/A | N/A |
Margin Expansion Despite International Challenges
The company's gross margin improved to 50%, reflecting a 170 basis point increase from the previous year. This growth was driven by enhanced cultivation efficiency and effective labor cost management. However, there was a noted drag of 140 basis points from the international segment, attributed to price compression in Germany. Curaleaf's domestic gross margin stood at 51%, indicating the strength of its U.S. operations amidst ongoing retail price pressures.
Strategic Outlook and Growth Opportunities
Looking ahead, Curaleaf expects domestic revenue growth to persist, driven by a combination of operational excellence and strategic initiatives. The company anticipates third-quarter revenue to increase in low single digits sequentially, projecting approximately $347 million. Management highlighted the potential for significant growth in states like Georgia, Texas, and Virginia, where regulatory advancements could open new market opportunities.
In the international arena, Curaleaf reported a robust 26% growth, largely driven by operations in the UK, Germany, and Poland. The successful launch of new products, including the Huala Value brand, and increasing patient counts in the UK, were key contributors. Furthermore, Curaleaf is poised to expand its footprint in Spain and France, with expectations of capturing market share as these countries advance their medical cannabis programs.
Regulatory Changes as a Catalyst for Growth
A pivotal moment for the U.S. cannabis industry occurred in April when the Department of Justice moved to reschedule state-regulated medical cannabis to Schedule 3 under the Controlled Substances Act. This change is expected to enhance access to traditional financial services for cannabis operators, including Curaleaf, and may facilitate the company's potential uplisting to a major exchange.
Boris Jordan, Chairman and CEO, emphasized that the rescheduling could lead to a substantial market reset and increased consumer traffic, particularly as the industry prepares for the anticipated shutdown of unregulated hemp-derived products. Curaleaf is strategically positioned to leverage these regulatory advancements, aiming for a robust recovery in cannabis demand by 2027.
Frequently Asked Questions
Did CURA beat earnings estimates in Q2 2026?
Yes, Curaleaf reported a net income of $12.5 million, compared to a consensus estimate of a net loss, marking a significant improvement from the $48 million loss reported in the previous year.
What drove the revenue growth for CURA in Q2 2026?
Revenue growth was driven by a 7% increase in domestic sales and a 26% surge in international sales, supported by operational improvements and a successful rollout of new products in key markets.
How is CURA managing international supply chain challenges?
Curaleaf is diversifying its supplier base to reduce dependency on single providers and plans to increase its internal production capacity to 50-75% over the next 6-12 months, aiming to improve margins in its international operations.
What is CURA's outlook for the next quarter?
Curaleaf expects third-quarter revenue to increase in low single digits sequentially, projecting approximately $347 million, while continuing to focus on cost management and operational efficiencies.
Curaleaf's strategic initiatives and regulatory developments position the company favorably for continued growth, making it a key player in the evolving cannabis landscape.
This analysis is based on public earnings call materials and is not investment advice.
